277 related articles for article (PubMed ID: 29687244)
1. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types.
Lacy S; Yang B; Nielsen J; Miles D; Nguyen L; Hutmacher M
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1071-1082. PubMed ID: 29687244
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
3. Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma.
Nguyen L; Chapel S; Tran BD; Lacy S
J Clin Pharmacol; 2019 Nov; 59(11):1551-1561. PubMed ID: 31187515
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
Yu M; Gao Z; Dai X; Gong H; Zhang L; Chen X; Zhong DF; Sy SK
Clin Pharmacokinet; 2017 Jan; 56(1):65-76. PubMed ID: 27379402
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults.
Nguyen L; Benrimoh N; Xie Y; Offman E; Lacy S
Anticancer Drugs; 2016 Aug; 27(7):669-78. PubMed ID: 27139820
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor.
Markowitz JN; Fancher KM
Pharmacotherapy; 2018 Mar; 38(3):357-369. PubMed ID: 29283440
[TBL] [Abstract][Full Text] [Related]
9. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
Castellano D; Pablo Maroto J; Benzaghou F; Taguieva N; Nguyen L; Clary DO; Jonasch E
Cancer Treat Rev; 2020 Sep; 89():102062. PubMed ID: 32659623
[TBL] [Abstract][Full Text] [Related]
10. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
Lacy S; Nielsen J; Yang B; Miles D; Nguyen L; Hutmacher M
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1061-1070. PubMed ID: 29667066
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.
Lacy SA; Miles DR; Nguyen LT
Clin Pharmacokinet; 2017 May; 56(5):477-491. PubMed ID: 27734291
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib.
Miles DR; Wada DR; Jumbe NL; Lacy SA; Nguyen LT
Anticancer Drugs; 2016 Apr; 27(4):328-41. PubMed ID: 26825867
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
Miles DR; Lacy SA; Wada DR; Milwee S; Yaron Y; Nguyen LT
Cancer Chemother Pharmacol; 2017 Aug; 80(2):295-306. PubMed ID: 28634649
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib for the treatment of advanced medullary thyroid cancer.
Nagilla M; Brown RL; Cohen EE
Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib for the treatment of kidney cancer.
Abdelaziz A; Vaishampayan U
Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer.
Ly NS; Li J; Faggioni R; Roskos LK; Brose MS
Clin Pharmacokinet; 2023 Apr; 62(4):587-598. PubMed ID: 36869986
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models.
Chen W; Chen R; Li J; Fu Y; Yang L; Su H; Yao Y; Li L; Zhou T; Lu W
J Pharmacol Exp Ther; 2018 Jan; 364(1):13-25. PubMed ID: 29084815
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
